Treatment of Atrial Fibrillation: Dronedarone -- Differences Between Amiodaron and Other Antiarrhyth

Twitter icon
Facebook icon
LinkedIn icon
e-mail icon
Google icon

March 14, Sunday 4:30 PM to 6:00 PM
An ATHENA trial showed that after a 30-month follow up of more than 4,000 atrial fibrillation (AF) and atrial flutter patients, cardiovascular hospitalizations and death occurred 24 percent less in patients administered dronedarone than in those administered a placebo. A post-hoc analysis of the ATHENA trial also showed that those on the drug had a reduction in stroke.

While amiodarone has been on the U.S. market since the mid-1980s, dronedarone is a new-comer. How do physicians gauge the difference between drugs that have been around for decades with newer-generation therapies? In this session. Dr. Peter Smith from Marshfield, Wis., will present anti-arrhythmic case presentations and a panel of distinguished physicians in the EP field will discuss the ramifications.

Location: Room B402

Speaker Information:
Peter N. Smith, MD, Marshfield, Wis.
Melanie T. Gura, MD, Hudson, Ohio
Joseph S. Alpert, MD, Tucson, Ariz.
Sangeeta B. Shah, MD, Harvey, La.